Predictors of Response to Topical Ruxolitinib in Non‐segmental Vitiligo: A Narrative Review
Australasian Journal of Dermatology · 2026
DOI: 10.1111/ajd.70090 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Australasian Journal of Dermatology, 2026. Verfasst von Luca Bettolini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Nitriles, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Topical ruxolitinib 1.5% cream is the first approved therapy for repigmentation in non‐segmental vitiligo. However, treatment response varies, and reliable predictors of efficacy remain undefined. This narrative review examined clinical trials and observational studies investigating factors associated with response to ruxolitinib cream. A comprehensive search of MEDLINE, Cochrane CENTRAL and ClinicalTrials.gov (through June 2025) identified 14 eligible studies. Anatomical site was the most consistent predictor, with facial lesions showing the highest repigmentation rates and acral areas demonstrating poor response. Early clinical improvement was associated with better long‐term outcomes. Long‐term data indicated that repigmentation can persist after treatment discontinuation in a substantial proportion of patients. Demographic and disease‐related variables, including age, sex, disease duration and phototype, showed mixed results across studies. Adjunctive narrowband UVB improved repigmentation in initial non‐responders but provided limited benefit in early responders. Exploratory biomarker data suggested that Th2 cytokine profiles and reductions in CXCL10 levels may be linked to response, although these findings remain unvalidated. Overall, anatomical location and early clinical response appear to be the most reliable indicators of ruxolitinib efficacy. Further studies with standardized endpoints and predictive modelling are needed to guide individualized treatment strategies in vitiligo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.
- Department of Medicine and Surgery, University of Insubria, Varese, Italy.
- Department of Medicine, Institute of Dermatology, University of Udine, Udine, Italy.
- Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
- Dermatology Unit, Fondazione IRCCS ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Medicine and Technology, University of Insubria, Varese, Italy.
ORCID-Profile: Luca Bettolini, Vincenzo Maione, Andrea Carugno, Zeno Fratton, Enzo Errichetti, Mariateresa Rossi, Stefano Bighetti
Zitieren
APA
Bettolini, L., Maione, V., Carugno, A., Fratton, Z., Errichetti, E., Crivellari, M., Cartocci, A., Maronese, C. A., Venturini, M., Zerbinati, N., Rossi, M., & Bighetti, S. (2026). Predictors of Response to Topical Ruxolitinib in Non‐segmental Vitiligo: A Narrative Review. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70090
Vancouver
Bettolini L, Maione V, Carugno A, Fratton Z, Errichetti E, Crivellari M, et al. Predictors of Response to Topical Ruxolitinib in Non‐segmental Vitiligo: A Narrative Review. Australasian Journal of Dermatology. 2026. doi:10.1111/ajd.70090
BibTeX
@article{Bettolini2026,
author = {Bettolini, Luca and Maione, Vincenzo and Carugno, Andrea and Fratton, Zeno and Errichetti, Enzo and Crivellari, Matteo and Cartocci, Alessandra and Maronese, Carlo Alberto and Venturini, Marina and Zerbinati, Nicola and Rossi, Mariateresa and Bighetti, Stefano},
title = {Predictors of Response to Topical Ruxolitinib in Non‐segmental Vitiligo: A Narrative Review},
journal = {Australasian Journal of Dermatology},
year = {2026},
doi = {10.1111/ajd.70090}
}
EUVIMED